Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Relapsed Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsed Chronic Lymphocytic Leukemia (CLL). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Relapsed Chronic Lymphocytic Leukemia (CLL). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Table of Contents
Table of Contents2
List of Tables 4
List of Figures 6
Introduction 7
Relapsed Chronic Lymphocytic Leukemia (CLL) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Relapsed Chronic Lymphocytic Leukemia (CLL) 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Relapsed Chronic Lymphocytic Leukemia (CLL) 31
Dec 09, 2013: Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia 31
Dec 09, 2013: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol in CLL and MM Studies 31
Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL 33
Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 33
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
F. Hoffmann-La Roche Ltd. 35
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 35
Pharmacyclics, Inc. 37
Clinical Trial Overview of Pharmacyclics, Inc. 37
GlaxoSmithKline plc 38
Clinical Trial Overview of GlaxoSmithKline plc 38
Celgene Corporation 39
Clinical Trial Overview of Celgene Corporation 39
AbbVie Inc. 40
Clinical Trial Overview of AbbVie Inc. 40
Janssen Global Services, LLC 41
Clinical Trial Overview of Janssen Global Services, LLC 41
Sanofi 42
Clinical Trial Overview of Sanofi 42
Gilead Sciences, Inc. 43
Clinical Trial Overview of Gilead Sciences, Inc. 43
Bristol-Myers Squibb Company 44
Clinical Trial Overview of Bristol-Myers Squibb Company 44
AstraZeneca PLC 45
Clinical Trial Overview of AstraZeneca PLC 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
The University of Texas M. D. Anderson Cancer Center 47
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 47
Ohio State University Comprehensive Cancer Center 48
Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 48
Massachusetts General Hospital 49
Clinical Trial Overview of Massachusetts General Hospital 49
Eastern Cooperative Oncology Group 50
Clinical Trial Overview of Eastern Cooperative Oncology Group 50
Fred Hutchinson Cancer Research Center 51
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 51
Roswell Park Cancer Institute 52
Clinical Trial Overview of Roswell Park Cancer Institute 52
University of Kentucky 53
Clinical Trial Overview of University of Kentucky 53
Beth Israel Deaconess Medical Center 54
Clinical Trial Overview of Beth Israel Deaconess Medical Center 54
Duke University 55
Clinical Trial Overview of Duke University 55
Five Key Clinical Profiles 56
Appendix 182
Abbreviations 182
Definitions 182
Research Methodology 183
Secondary Research 183
About GlobalData 184
Contact Us 184
Disclaimer 184
Source 185

List of Tables
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15
Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 35
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014* 37
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 38
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 39
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 40
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Global Services, LLC, 2014* 41
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 42
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 43
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 44
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 45
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 47
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University Comprehensive Cancer Center, 2014* 48
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 49
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 50
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 51
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014* 52
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Kentucky, 2014* 53
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Beth Israel Deaconess Medical Center, 2014* 54
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 55

List of Figures
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 15
Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 183

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Regulatory Affairs Outsourcing Market (Services: Regulatory Affairs, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation and Others) - Global Industry Analysis, Size, Sha

Regulatory Affairs Outsourcing Market (Services: Regulatory Affairs, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation and Others) - Global Industry Analysis, Size, Sha

  • $ 4 795
  • Industry report
  • October 2014
  • by Transparency Market Research

This report on the regulatory affairs outsourcing market studies the current as well as future prospects of the market globally. Regulatory affairs outsourcing is rapidly gaining popularity in the global ...

Proteomics Markets for Research and IVD Applications

Proteomics Markets for Research and IVD Applications

  • $ 4 200
  • Industry report
  • September 2014
  • by Kalorama Information

This Kalorama Information report defines markets and identifies trends for proteomics applications, both in their research use and in IVD. Proteomics is the study of proteins, including the study of the ...

Biologicals in Oncology Drug Pipeline Update 2014

Biologicals in Oncology Drug Pipeline Update 2014

  • $ 3 749
  • Industry report
  • October 2014
  • by Bioseeker

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1784 biological ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.